Catalyst Pharmaceuticals Stock Performance
| CPRX Stock | USD 15.11 0.00 0.00% |
Catalyst Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.81, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Catalyst Pharmaceuticals will likely underperform. Catalyst Pharmaceuticals right now shows a risk of 2.71%. Please confirm Catalyst Pharmaceuticals jensen alpha, potential upside, as well as the relationship between the Potential Upside and accumulation distribution , to decide if Catalyst Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Catalyst Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Catalyst Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.43 | Five Day Return (2.55) | Year To Date Return (12.97) | Ten Year Return 644.5 | All Time Return 144.1 |
1 | Disposition of 2353 shares by Brian Elsbernd of Catalyst Pharmaceuticals subject to Rule 16b-3 | 02/15/2024 |
2 | Exercise or conversion by David Tierney of 4000 shares of Catalyst Pharmaceuticals subject to Rule 16b-3 | 02/16/2024 |
3 | 3 Biopharma Stocks You Dont Want to Miss in the New Bull Market | 03/05/2024 |
4 | Citi sets 27 target on Catalyst Pharma stock, cites growth potential | 03/14/2024 |
5 | Crinetics Pharmaceuticals Stock Jumps 19.1 percent Will It Continue to Soar | 03/20/2024 |
6 | Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium | 03/27/2024 |
7 | Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome Awareness Day | 03/28/2024 |
8 | Catalyst Pharmaceutical Gains As Market Dips What You Should Know - Yahoo Movies Canada | 04/01/2024 |
9 | Acquisition by David Tierney of 25000 shares of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3 | 04/08/2024 |
10 | Catalyst Pharmaceuticals director sells 2,000 in stock | 04/10/2024 |
11 | Catalyst Pharmaceuticals, Inc. is largely controlled by institutional shareholders who own 65 percent of the company | 04/18/2024 |
12 | Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May | 04/25/2024 |
| Begin Period Cash Flow | 298.4 M | |
| Free Cash Flow | -54.9 M |
Catalyst |
Catalyst Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,477 in Catalyst Pharmaceuticals on January 30, 2024 and sell it today you would earn a total of 12.00 from holding Catalyst Pharmaceuticals or generate 0.81% return on investment over 90 days. Catalyst Pharmaceuticals is currently generating 0.0485% in daily expected returns and assumes 2.7059% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Catalyst, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Catalyst Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catalyst Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Catalyst Pharmaceuticals, and traders can use it to determine the average amount a Catalyst Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0179
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CPRX |
Estimated Market Risk
| 2.71 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Catalyst Pharmaceuticals is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Catalyst Pharmaceuticals by adding it to a well-diversified portfolio.
Catalyst Pharmaceuticals Fundamentals Growth
Catalyst Stock prices reflect investors' perceptions of the future prospects and financial health of Catalyst Pharmaceuticals, and Catalyst Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Catalyst Stock performance.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 1.62 B | ||||
| Shares Outstanding | 118.01 M | ||||
| Price To Earning | 23.62 X | ||||
| Price To Book | 4.63 X | ||||
| Price To Sales | 4.51 X | ||||
| Revenue | 398.2 M | ||||
| Gross Profit | 160.02 M | ||||
| EBITDA | 119.95 M | ||||
| Net Income | 71.41 M | ||||
| Cash And Equivalents | 220.79 M | ||||
| Cash Per Share | 2.15 X | ||||
| Total Debt | 3.56 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | 143.6 M | ||||
| Earnings Per Share | 0.63 X | ||||
| Market Capitalization | 1.76 B | ||||
| Total Asset | 471.91 M | ||||
| Retained Earnings | 121.27 M | ||||
| Working Capital | 143.27 M | ||||
| Current Asset | 59.9 M | ||||
| Current Liabilities | 3.44 M | ||||
About Catalyst Pharmaceuticals Performance
To evaluate Catalyst Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Catalyst Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Catalyst Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Catalyst Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Catalyst's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 67.55 | 67.05 | |
| Return On Tangible Assets | 0.26 | 0.27 | |
| Return On Capital Employed | 0.22 | 0.23 | |
| Return On Assets | 0.15 | 0.16 | |
| Return On Equity | 0.18 | 0.19 |
Things to note about Catalyst Pharmaceuticals performance evaluation
Checking the ongoing alerts about Catalyst Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Catalyst Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Catalyst Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Catalyst Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| About 73.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May |
- Analyzing Catalyst Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Catalyst Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Catalyst Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Catalyst Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Catalyst Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Catalyst Pharmaceuticals' stock. These opinions can provide insight into Catalyst Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.